Toby A. Eyre

Also affiliated with John Radcliffe Hospital, University of Oxford, Oxford University Hospitals NHS Trust

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 11 papers. Top paper: “Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia”.

Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia

Blood(2025)10.1182/blood.2024027009

N/A

0.452DataRank · unranked

6 citations

Bastien Nguyen, Sai Prasad Desikan, Helen Won, Shady I. Tantawy, Samuel McNeely +22 more

International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations

Blood(2025)10.1182/blood.2024028064

N/A

0.425DataRank · unranked

16 citations

Monia Marchetti, Othman Al‐Sawaf, Ohad Benjamini, Alexey V. Danilov, Matthew S. Davids +24 more

Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents

Blood Advances(2020)10.1182/bloodadvances.2020001956

N/A

0DataRank · unranked

86 citations

Peter Dreger, Jennifer R. Brown, Oscar Lahoud, Toby A. Eyre, Danielle M. Brander +20 more

COVID-19 in patients with CLL: improved survival outcomes and update on management strategies

Blood(2021)10.1182/blood.2021011841

N/A

0DataRank · unranked

70 citations

Toby A. Eyre, Meghan C. Thompson, Nicole Lamanna, Alexander Coltoff, Matthew S. Davids +47 more

Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib

Haematologica(2022)10.3324/haematol.2022.281402

N/A

0DataRank · unranked

12 citations

Neline Kriek, Tanya Sage, Suzannah J. Rawlings, Catherine Prodger, Murali Kesavan +8 more

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Blood(2020)10.1182/blood.2020006965

N/A

0DataRank · unranked

318 citations

Lindsey E. Roeker, Nicole Lamanna, John N. Allan, Lori A. Leslie, John M. Pagel +57 more

Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials

Blood Advances(2024)10.1182/bloodadvances.2023011307

N/A

0DataRank · unranked

18 citations

Jeff P. Sharman, Paolo Ghia, Jennifer A. Woyach, Toby A. Eyre, Wojciech Jurczak +7 more

Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial

Haematologica(2024)10.3324/haematol.2024.285754

N/A

0DataRank · unranked

13 citations

Michael Wang, Lindsey E. Roeker, Krish Patel, Jennifer A. Woyach, William G. Wierda +30 more

Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies

Acta Haematologica(2024)10.1159/000539587

N/A

0DataRank · unranked

1 citations

Catherine C. Coombs, Nirav N. Shah, Wojciech Jurczak, Jennifer A. Woyach, Chan Y. Cheah +16 more

Patient-Reported Outcomes (PROs) Among Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Receiving Pirtobrutinib: Analysis from the BRUIN Phase 1/2 Study

Blood(2023)10.1182/blood-2023-186145

N/A

0DataRank · unranked

0 citations

Jennifer A. Woyach, Jennifer R. Brown, Paolo Ghia, Lindsey E. Roeker, Krish Patel +17 more

Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3815

N/A

0DataRank · unranked

116 citations

Lindsey E. Roeker, Ryan Jacobs, Brian T. Hill, Nicole Lamanna, Danielle M. Brander +49 more